MSCs for Stroke Therapy | Stemodontics®
BACK

MSCs for Stroke Therapy

This article reviews recent studies using mesenchymal stem cells for stroke therapy and concludes that more research is needed to determine the effectiveness of this therapy.

ABSTRACT

From the Lab to Patients: a Systematic Review and Meta-Analysis of Mesenchymal Stem Cell Therapy for Stroke.

Transl Stroke Res. 2019 Oct 25. doi: 10.1007/s12975-019-00736-5. [Epub ahead of print]

Lalu MM1,2,3, Montroy J4, Dowlatshahi D4,5, Hutton B6,7, Juneau P4, Wesch N4, Y Zhang S8, McGinn R9,8, Corbett D10,11, Stewart DJ10,12, A Fergusson D4,6.

Author information

  1. Department of Anesthesiology and Pain Medicine, The Ottawa Hospital Research Institute, Room B307, 1053 Carling Ave, Mail Stop 249, Ottawa, ON, K1Y 4E9, Canada. [email protected].
  2. Clinical Epidemiology Program, Blueprint Translational Group, The Ottawa Hospital Research Institute, Ottawa, Canada. [email protected].
  3. Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada. [email protected].
  4. Clinical Epidemiology Program, Blueprint Translational Group, The Ottawa Hospital Research Institute, Ottawa, Canada.
  5. Department of Medicine, Neurology, The Ottawa Hospital, Ottawa, Canada.
  6. Knowledge Synthesis Group, Ottawa Hospital Research Institute, Ottawa, Canada.
  7. School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
  8. Faculty of Medicine, University of Ottawa, Ottawa, Canada.
  9. Department of Anesthesiology and Pain Medicine, The Ottawa Hospital Research Institute, Room B307, 1053 Carling Ave, Mail Stop 249, Ottawa, ON, K1Y 4E9, Canada.
  10. Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada.
  11. Canadian Partnership for Stroke Recovery, Ottawa, Canada.
  12. Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.

Abstract

There may be the potential to improve stroke recovery with mesenchymal stem cells (MSCs); however, questions about the efficacy and safety of this treatment remain. To address these issues and inform future studies, we performed a preclinical and clinical systematic review of MSC therapy for subacute and chronic ischemic stroke. MEDLINE, Embase, the Cochrane Register of Controlled Trials, and PubMed were searched. For the clinical review, interventional and observational studies of MSC therapy in ischemic stroke patients were included. For the preclinical review, interventional studies of MSC therapy using in vivo animal models of subacute or chronic stroke were included. Measures of safety and efficacy were assessed. Eleven clinical and 76 preclinical studies were included. Preclinically, MSC therapy was associated with significant benefits for multiple measures of motor and neurological function. Clinically, MSC therapy appeared to be safe, with no increase in adverse events reported (with the exception of self-limited fever immediately following injection). However, the efficacy of treatment was less apparent, with significant heterogeneity in both study design and effect size being observed. Additionally, in the only randomized phase II study to date, efficacy of MSC therapy was not observed. Preclinically, MSC therapy demonstrated considerable efficacy. Although MSC therapy demonstrated safety in the clinical setting, efficacy has yet to be determined. Future studies will need to address the discordance in the continuity of evidence as MSC therapy has been translated from “bench-to-bedside”.

 

PMID:31654281

DOI:10.1007/s12975-019-00736-5